---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Heterogeneity of treatment effect"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Heterogeneity of treatment effect. Topics: Intensity of the psychedelic experience and Week 3 response in the phase 2b trial, Therapeutic alliance and Week 3 response in the phase 2b trial, Pretreatment clinical characteristics and the psychedelic experience, Antidepressant discontinuation before dosing, and 11 further topics. 15 evidence topics quoted from 18 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Intensity of the psychedelic experience and Week 3 response in the phase 2b trial

> “The mean intensity of psychedelic effects was dose-related, but distributions of scores for different doses overlapped considerably.”
> “At the 25 mg dose, 5D-ASC dimensions Oceanic Boundlessness (Pearson correlation coefficient r = -0.508) and Visual Restructuralization (r = -0.516), and EBI (r = -0·637) were the variables with the strongest correlation to the Week 3 change from Baseline in MADRS score.”
> “The existence of correlation does not establish causation and exploratory findings require further replication, preferably in larger independent samples.”

Source: [Goodwin et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39706482/)

<a id="topic-2.2.2.3-2"></a>

### Therapeutic alliance and Week 3 response in the phase 2b trial

> “Change from Baseline to Week 3 MADRS scores showed weaker correlations with pre-dosing therapeutic alliance (-0.178) than with measures of the psychedelic experience: EBI (-0.637), Oceanic Boundlessness (-0.508), and Visual Restructuralization (-0.516).”
> “The effects of the alliance itself on therapeutic efficacy were either limited or absent.”

Source: [Goodwin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41881122/)

<a id="topic-2.2.2.3-3"></a>

### Pretreatment clinical characteristics and the psychedelic experience

> “Dose was the strongest and most consistent predictor of the psychedelic experience.”
> “Positive affect, lower generalized anxiety symptoms, higher executive functioning, and greater personality disorder symptoms had significant effects on different aspects of the subjective psychedelic experience.”

Source: [Kirlić et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41362124/)

<a id="topic-2.2.2.3-4"></a>

### Antidepressant discontinuation before dosing

> “Antidepressant drug discontinuation was not related to worsening of depression severity before Baseline.”
> “Psilocybin treatment efficacy and the subjective psychedelic experience did not appear to be compromised by antidepressant drug discontinuation.”

Source: [Marwood et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39427449/)

> “No significant differences were found between medication discontinued (n = 18) and unmedicated at screening (UAS) (n = 9) groups in clinician rated depression (p = 0.759), self-reported depression (p = 0.215), anxiety (p = 0.178), and suicidality (p = 0.882) symptoms over time, with both groups having clinically significant benefits on all outcomes assessed.”

Source: [Chisamore et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11948223/)

<a id="topic-2.2.2.3-5"></a>

### Concomitant SSRI treatment in an open-label adjunctive study

> “in fact, the response and remission rates were higher in the current study (42% response and remission rates at Week 3 verses 37% and 29%, respectively).”
> “Future research should examine whether the outcomes of psilocybin as a monotherapy or as an adjunct to SSRIs remain comparable in a longer term follow up.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-2.2.2.3-6"></a>

### Severe treatment resistance and comorbid PTSD in an open-label single-site study

> “Patients whose illness fails to respond to at least five treatments may be considered to have severely treatment-resistant depression (TRD).”
> “Depressive symptoms were significantly decreased at week 3 (MADRS least-squares mean change=-15.8, 95% CI=-25.4 to -6.3) and Week 12 (MADRS least-squares mean change=-17.2, 95% CI=-25.2 to -9.1).”
> “In exploratory analyses, the Oceanic Boundlessness (OB) dimension of the psychedelic experience correlated with post-dosing antidepressant responses.”
> “Patients with comorbid PTSD (N=5) showed significantly less antidepressant effect of psilocybin.”

Source: [Aaronson et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39741440/)

<a id="topic-2.2.2.3-7"></a>

### Veterans with severe treatment resistance in the same open-label study

> “Of 15 participants, 60 % met response and 53 % met remission criteria at Week 3.”
> “Co-morbid PTSD did not significantly influence study outcomes.”
> “The psychedelic experience reported in 5D-ASC did not correlate with response.”

Source: [Ellis et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39343309/)

<a id="topic-2.2.2.3-8"></a>

### Number of prior treatment failures: company statements

> “We haven't yet done an analysis of the response or remission rates or other outcome measures based upon the number of lines of treatment that have failed these patients within our studies.”
> “because we were studying treatment-resistant depression, we were required to study failures after two failures. We would not have any data on the zero to two failures.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.2.2.3-9"></a>

### Early prediction of response from language in the post-dosing session

> “While the phase-IIb results are promising, the treatment works for a portion of the population and early prediction of outcome is a key objective as it would allow early identification of those likely to require alternative treatment.”
> “Two multinomial logistic regression models were fit to predict responder status at week 3 and through week 12.”
> “Cross-validation of these models resulted in 85% and 88% accuracy and AUC values of 88% and 85%.”

Source: [Dougherty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226623/)

<a id="topic-2.2.2.3-10"></a>

### Control-group response in psilocybin trials compared with SSRI and esketamine trials

> “MADRS response rates for control treatments in SSRI trials were 14 percentage points higher than in psilocybin trials and in esketamine trials were 23 percentage points higher than in psilocybin trials.”
> “The poor control treatment outcomes in psilocybin trials suggest that it may not be as broadly effective for depression as estimated.”

Source: [Hieronymus et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12311713/)

> “However, the effect size (standardised mean difference) of high dose psilocybin decreased from large (0.88) to small (0.31) when the reference arm changed from placebo response in the psychedelic trials to antidepressant trials.”

Source: [Hsu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337322/)

<a id="topic-2.2.2.3-11"></a>

### Trial methodology and study size as moderators in meta-analyses

> “The subgroup analyses found larger effects, albeit non-significant differences in subgroup heterogeneity, associated with studies that administered psilocybin in bodyweight-adjusted doses and provided longer preparation, dosing, and integration sessions and provided non-manualized psychotherapy.”

Source: [Syed et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41587629/)

> “Effects were moderate and attenuated in larger and better-controlled studies.”

Source: [Borgogna et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12449434/)

<a id="topic-2.2.2.3-12"></a>

### Dose-response by type of depression

> “The determined 95% effective doses per day (ED95) were 8.92, 24.68, and 36.08 mg/70 kg for patients with secondary depression, primary depression, and both subgroups, respectively.”

Source: [Perez et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37557019/)

<a id="topic-2.2.2.3-13"></a>

### Regulatory expectations for characterizing variability in response

> “In particular, the relationship between characteristics of the acute psychedelic experience and clinical improvement, as well as the need for dose adjustments should be investigated.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-2.2.2.3-14"></a>

### Subgroups planned in the ICER assessment

> “As data permit, we will also plan to examine subgroups of patients suggested by patients and clinical experts.”
> “Age (e.g., 18-64 vs. ≥ 65 years of age)”
> “Number of prior antidepressant trials (e.g., two, three, four)”
> “Concomitant use of medication for mental health (e.g., antidepressants, antipsychotics)”
> “Prior exposure to psychedelics”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.2.2.3-15"></a>

### Payer requests for subgroup data

> “Other data participants saw as important included subgroup analyses to elucidate the appropriate treatment population and potential budget impact, and data to assess cost-effectiveness.”
> “They also highlighted that treatment effect is likely more variable given the nature of the treatment and additional, longer-term data will be necessary to increase the predictability of response.”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
